A practical reference on AOD9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
As mayor, Bukele began a "reordering" ("reordenamiento") to revitalize the city's historic downtown area and combat crime. On the day Bukele took office, he reverted the names of two streets in San Salvador (Calle Mayor Roberto D'Aubuisson and Boulevard Coronel José Arturo Castellanos) to Calle San Antonio Abad and Boulevard Venezuela, respectively. Both names had been changed by Bukele's predecessor, Norman Quijano. Zamora, who had become a member of San Salvador's municipal council, stated that the names were reverted due to flaws in the initial renaming process. He added that another street would be named in honor of Castellanos, who provided fake Salvadoran passports to 40,000 Central European Jews to help them escape the Holocaust. Bukele renamed 89 Avenida Norte in honor of Castellanos in June 2016. In December 2016, Bukele inaugurated the Cuscatlán Market to encourage street vendors to relocate their businesses. Many vendors refused to move, despite the market. Political opponents and investigative journalists accused him of negotiating with gangs to organize its construction, since it was located in gang-controlled territory. In January 2016, Bukele began a "San Salvador 100% Illuminated" campaign to "have a light on every corner of San Salvador" to combat crime in the city. The campaign was completed by May 2016. He also installed video-surveillance cameras in parts of San Salvador that were severely affected by crime. Bukele inaugurated the renovated downtown Gerardo Barrios Plaza in October 2017, and the new downtown Lineal Plaza in April 2018.
=== Barney Calhoun === Barney Calhoun is the player character in Half-Life: Blue Shift and a major character in Half-Life 2 as well as Half-Life 2: Episode One. Michael Shapiro provided Barney's voice in the games of the Half-Life series. Scott Lynch, Valve's chief operating officer, lent his face to the game for use in-game as Barney in Half-Life 2. Barney's name stemmed from the earlier alpha versions of Half-Life in which the model for the security guards held a resemblance to actor Don Knotts, inspiring comparisons with Knotts's character Barney Fife from The Andy Griffith Show, which in the United States has long been a disparaging term for an inept policeman or security guard. Initially, the "Barneys" were intended to be hostile NPCs who would attack the player. In Half-Life: Blue Shift, the playable Barney progresses through Black Mesa to escape the events of the Resonance Cascade and is able to do so, in contrast to Gordon Freeman and Adrian Shephard, who are held in stasis. In Half-Life 2, Barney works as a mole for the Lambda Resistance in the Combine Civil Protection Forces. He provides the player information in the first chapter, leading him to Kleiner and Vance, and in the end of the second chapter, he provides the player with his crowbar. The fact that Barney owes Gordon Freeman a beer is a running gag in the series.
Some exceptions include cellulose and methane, as these compounds are easily separated. Another advantage of methane for compound-specific measurements is the lack of hydrogen exchange. Cellulose has exchangeable hydrogen, but chemical derivatization can prevent swapping of cellulose hydrogen with water or mineral hydrogen sources. Cellulose and methane studies in the 1970s and 1980s set the standard for modern hydrogen isotope geochemistry. Measurement of individual compounds was made possible in the late 1990s and early 2000s with advances in mass spectrometry. The Thermo Delta+XL transformed measurements as the first instrument capable of compound specific isotope analysis. It was then possible to look at smaller samples with more precision. Hydrogen isotope applications quickly emerged in petroleum geochemistry by measuring oil, paleoclimatology by observing lipid biomarkers, and ecology by constructing trophic dynamics. Advances are underway in the clumped-isotope composition of methane after development of the carbonate thermometer. Precise measurements are also enabling focus on microbial biosynthetic pathways involving hydrogen. Ecologists studying trophic levels are especially interested in compound specific measurements for reconstructing past diets and tracing predator-prey relationships. Highly advanced machines now promise position-specific hydrogen-isotope analysis of biomolecules and natural gas.
A classic example is two seeds of genetically identical corn, one placed in a temperate climate and one in an arid climate (lacking sufficient waterfall or rain). While the average height the two corn stalks could grow to is genetically determined, the one in the arid climate only grows to half the height of the one in the temperate climate due to lack of water and nutrients in its environment.
Sources: en.wikipedia.org
== Awards and recognition == 1997: Newcomb Cleveland Prize 1998: W. Alden Spencer Award 1999: Albert Lasker Basic Medical Research Award 2000: Rosenstiel Award 2001: Gairdner Foundation International Award 2003: Louisa Gross Horwitz Prize 2003: Nobel Prize in Chemistry
DMT derived from plant-based sources has been used as an entheogen in South America for thousands of years. DMT was first synthesized in 1931 by Canadian chemist Richard Manske. In general, its discovery as a natural product is credited to Brazilian chemist and microbiologist Oswaldo Gonçalves de Lima, who isolated an alkaloid he named nigerina (nigerine) from the root bark of Mimosa tenuiflora in 1946. However, in a careful review of the case Jonathan Ott shows that the empirical formula for nigerine determined by Gonçalves de Lima, which notably contains an atom of oxygen, can match only a partial, "impure" or "contaminated" form of DMT. It was only in 1959, when Gonçalves de Lima provided American chemists a sample of Mimosa tenuiflora roots, that DMT was unequivocally identified in this plant material. Less ambiguous is the case of isolation and formal identification of DMT in 1955 in seeds and pods of Anadenanthera peregrina by a team of American chemists led by Evan Horning (1916-1993). Since 1955, DMT has been found in a number of organisms: in at least fifty plant species belonging to ten families, and in at least four animal species, including one gorgonian and three mammalian species (including humans). In terms of a scientific understanding, the hallucinogenic effects of DMT were not uncovered until 1956 by Hungarian chemist and psychiatrist Stephen Szára.
7 January Hunt for the Death Star, about lethal energy bursts across the universe; Ray Klebesadel; music from the opening of You Only Live Twice; Bohdan Paczyński of Princeton University and unknown gamma-ray bursts; Stan Woosley of the University of California, Santa Cruz; the Compton Gamma Ray Observatory was deployed from 1991; Canadian Dale Frail of the Very Large Array in Socorro, New Mexico, and the W. M. Keck Observatory; the High Energy Transient Explorer 1 (HETE), launched incorrectly by a Northrop Grumman Pegasus on 4 November 1996, due to a faulty battery; music from Moonraker- Flight Into Space; Dutch researchers from the Anton Pannekoek Institute for Astronomy; the Italian BeppoSAX satellite, launched in April 1996; HETE 2 was launched on 9 October 2000.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.